Daiichi Sankyo Dogged by Renewed Quality Woes at Ranbaxy; FDA Mute on Details

Quality problems have reemerged at Ranbaxy Laboratories, casting yet another cloud over the corporate governance of Japanese parent Daiichi Sankyo, whose shares tumbled on news that a third plant of the Indian drug maker is now barred from US-bound imports...read more